Highlights of the important and the interesting from the world of healthcare: FDA panel to consider pulling Avandia. An expert panel of the U.S. Food and Drug Administration is planning a mid-July meeting to consider whether GlaxoSmithKline’s (NYSE: GSK) diabetes drug Avandia should be pulled from the market. Dr. Steven Nissen of the Cleveland Clinic […]
Highlights of the important and the interesting from the world of healthcare: Wellpoint suffers third security glitch of last 3.5 years: A security glitch at a WellPoint website may have publicly exposed the medical records and credit card numbers of about 470,000 customers, the third such breach the Indianapolis-based health insurer has reported in the […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A large clinical study of whether GlaxoSmithKline's Avandia diabetes drug is harmful to the heart has raised more questions than it answered. The study -- sponsored by Glaxo -- found that the drug does not raise heart attack risk, however, it does raise heart failure and bone fracture risks.